Limited coverage criteria – lacosamide tablets
Last updated on March 18, 2025
Return to Special Authority drug list
Generic name |
lacosamide | |
|---|---|---|
Strength & form |
50mg, 100mg, 150mg, 200mg tablet | |
Special Authority criteria |
Approval period |
|
For the treatment of partial-onset seizures in adults and to be used: As adjunctive therapy (used in combination with at least ONE other anti–epileptic drug) for partial–onset seizures AND After at least FOUR other anti–epileptic medications have been tried without success (names of previously tried therapies and response must be indicated on Special Authority request, see Special notes below) |
Indefinite |
Practitioner exemptions
- None
Special notes
- Special Authority requests should include documentation stating which other anti-epileptic drugs have been tried in adequate doses. Examples of other anti-epileptic drugs include:
- phenytoin (Dilantin®)
- carbamazepine (Tegretol®)
- gabapentin (Neurontin®)
- topiramate (Topamax®)
- lamotrigine (Lamictal®)
- levetiracetam (Keppra®)
- perampanel (Fycompa™)
- vigabatrin (Sabril®)
- eslicarbazepine acetate (Aptiom™)
- valproic acid (Epival®)